2009.10.09 – Cytopia achieves grant of further patent for JAK2 program
Cytopia achieves grant of further patent for JAK2 program
October 9th, 2009
Cytopia Ltd (ASX: CYT) announced today that it has further extended its patent protection over the validated JAK2 clinical target with the grant of a further patent in the United States of America.
Cytopia holds the exclusive licence to a family of patents for the drug targets JAK1 and JAK2. The issuance of US patent number 7593820 now augments this coverage by providing protection for the claimed methods of selecting or designing a compound which interacts with JAK2.
Cytopia has developed a library of novel small-molecule JAK2 inhibitors, with the most advanced compound CYT387 having recently been given clearance by the US Food and Drug Administration to enter clinical trials. A Phase I/II clinical trial in patients with myelofibrosis is expected to commence in the United States shortly.